Eprex

Phase 3Small molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

Eprex is one of 72 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Eprex

SShenyang Sunshine Pharmaceutical Co., LTD.

Phase 3

1 4

Vemlidy

Gilead

Preclinical

1 5

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

2 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Treatment

NCT03223961

Q2 2029

Phase 1/2Recruiting

MDS

NCT05181735

Clinical

Trials by Indication[1]

Tics2 trials

To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers

Unknown status·DDong-A ST Co., Ltd.·Phase 1·NCT02580006·42 enrolled

Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Completed·AAzidus Brasil·Phase 1·NCT03572647·40 enrolled

Erythropoietin2 trials

Completed·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 3·NCT02947438·207 enrolled

Terminated·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 4·NCT02522975·16 enrolled

Chronic Kidney Disease1 trial

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Terminated·AAzidus Brasil·Phase 3·NCT01695759·92 enrolled

Treatment1 trial

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active, not recruiting·GGroupe Francophone des Myelodysplasies·Phase 3·NCT03223961·124 enrolled

Safety and Efficacy1 trial

Study to Compare the Safety and Efficacy of UB-851 and Eprex®

Completed·UUBI Pharma Inc.·Phase 3·NCT02708914·269 enrolled

4 more indications

Anemia1 trial

Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients

Completed·CCinnagen·Phase 3·NCT03408639·156 enrolled

MDS1 trial

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting·GGroupe Francophone des Myelodysplasies·Phase 1/2·NCT05181735·150 enrolled

Biomarker1 trial

Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents

Unknown status·AAssociation Athletes For Transparency·Phase 1·NCT03276910·24 enrolled

Immunogenicity1 trial

To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)

Unknown status·DDong-A ST Co., Ltd.·Phase 3·NCT03521713·214 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Eprex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eprex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eprex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

Eprex

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Tics2 trials

Erythropoietin2 trials

Chronic Kidney Disease1 trial

Treatment1 trial

Safety and Efficacy1 trial

Anemia1 trial

MDS1 trial

Biomarker1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News